2018
MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA
Joseph R, Loriot Y, Perez-Gracia J, Dreicer R, Petrylak D, van der Heijden M, Hoffman-Censits J, Shen X, Fear S, Pavlova J, Rosenberg J. MP78-07 CLINICAL CHARACTERISTICS ASSOCIATED WITH EARLY PROGRESSION OR LONG-TERM RESPONSE FROM THE PHASE II IMVIGOR210 STUDY: ATEZOLIZUMAB IN LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA. Journal Of Urology 2018, 199: e1039. DOI: 10.1016/j.juro.2018.02.2555.Peer-Reviewed Original Research
2009
51 RADIOLOGIC PROGRESSION PREDICTS OVERALL SURVIVAL IN PATIENTS (PTS) WITH ANDROGEN INDEPENDENT PROSTATE CANCER (AIPC) WHO RECEIVED FIRST LINE DOCETAXEL; AN ANALYSIS FROM THE SPARC TRIAL
Witjes J, Petrylak D, Sartor O, Noursalehi M, Sternberg N, Wirth M, Billiet I, Petrone M, McKeam T, George M. 51 RADIOLOGIC PROGRESSION PREDICTS OVERALL SURVIVAL IN PATIENTS (PTS) WITH ANDROGEN INDEPENDENT PROSTATE CANCER (AIPC) WHO RECEIVED FIRST LINE DOCETAXEL; AN ANALYSIS FROM THE SPARC TRIAL. European Urology Open Science 2009, 8: 133. DOI: 10.1016/s1569-9056(09)60059-2.Peer-Reviewed Original Research
2008
Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916
Hussain M, Goldman B, Tangen C, Higano C, Petrylak D, Crawford E. Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916. Journal Of Clinical Oncology 2008, 26: 5015-5015. DOI: 10.1200/jco.2008.26.15_suppl.5015.Peer-Reviewed Original ResearchSATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PRIOR DOCETAXEL
Sternberg N, Sartor O, Petrylak D, Witjes F, Bodrogi I, Harper P, James N, Demkov T, Eymard J, Wirth M. SATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PRIOR DOCETAXEL. European Urology Open Science 2008, 7: 230. DOI: 10.1016/s1569-9056(08)60635-1.Peer-Reviewed Original Research
2007
4010 POSTER Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients
Sternberg C, Sartor O, Petrylak D, Witjes J, Bodrogi I, Harper P, Droz J, James N. 4010 POSTER Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients. European Journal Of Cancer Supplements 2007, 5: 282. DOI: 10.1016/s1359-6349(07)71078-9.Peer-Reviewed Original Research